Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsartan and Exercise-induced Erythropoiesis
NCT05269615Phase 4Recruiting
- Sponsor
- The University of Hong Kong
- Start
- Mar 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in cardiovascular disease (CVD) comparing Valsartan tablets with Placebo tablets (2 arms). Primary endpoints: Stroke volume at 10 weeks, Maximal oxygen consumption at 10 weeks and 1 more. Started Mar 2023; status: recruiting.
02
Drugs
valsartan
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT05269615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05269615.